JP2010537170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010537170A5 JP2010537170A5 JP2010521202A JP2010521202A JP2010537170A5 JP 2010537170 A5 JP2010537170 A5 JP 2010537170A5 JP 2010521202 A JP2010521202 A JP 2010521202A JP 2010521202 A JP2010521202 A JP 2010521202A JP 2010537170 A5 JP2010537170 A5 JP 2010537170A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- acid
- cell
- sample
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 48
- 206010028980 Neoplasm Diseases 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 46
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000002207 metabolite Substances 0.000 claims description 26
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 108010077895 Sarcosine Proteins 0.000 claims description 16
- 229940043230 sarcosine Drugs 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 12
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 12
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 claims description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 12
- 229940113082 thymine Drugs 0.000 claims description 10
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 claims description 8
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 claims description 8
- UZTFMUBKZQVKLK-UHFFFAOYSA-N 4-acetamidobutanoic acid Chemical compound CC(=O)NCCCC(O)=O UZTFMUBKZQVKLK-UHFFFAOYSA-N 0.000 claims description 6
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 108010024636 Glutathione Proteins 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 108010007979 Glycocholic Acid Proteins 0.000 claims description 6
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 6
- 229930010555 Inosine Natural products 0.000 claims description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 claims description 6
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- 239000004473 Threonine Substances 0.000 claims description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 6
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 claims description 6
- 229960005305 adenosine Drugs 0.000 claims description 6
- 235000009582 asparagine Nutrition 0.000 claims description 6
- 229960001230 asparagine Drugs 0.000 claims description 6
- 229940001468 citrate Drugs 0.000 claims description 6
- 229960003624 creatine Drugs 0.000 claims description 6
- 239000006046 creatine Substances 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- 229930195712 glutamate Natural products 0.000 claims description 6
- 235000013922 glutamic acid Nutrition 0.000 claims description 6
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 229960003180 glutathione Drugs 0.000 claims description 6
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims description 6
- 229940099347 glycocholic acid Drugs 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 229960003786 inosine Drugs 0.000 claims description 6
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 6
- 229960000367 inositol Drugs 0.000 claims description 6
- 229940049920 malate Drugs 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 229960001682 n-acetyltyrosine Drugs 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 6
- 229960003080 taurine Drugs 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- 229940116269 uric acid Drugs 0.000 claims description 6
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108010088390 Glycine N-Methyltransferase Proteins 0.000 claims description 4
- 102000008764 Glycine N-methyltransferase Human genes 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 108091070501 miRNA Proteins 0.000 claims description 4
- 239000002679 microRNA Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 239000002924 silencing RNA Substances 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000010261 cell growth Effects 0.000 claims 1
- 230000000630 rising effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95623907P | 2007-08-16 | 2007-08-16 | |
| US60/956,239 | 2007-08-16 | ||
| US7554008P | 2008-06-25 | 2008-06-25 | |
| US61/075,540 | 2008-06-25 | ||
| US13327908P | 2008-06-27 | 2008-06-27 | |
| US61/133,279 | 2008-06-27 | ||
| PCT/US2008/073318 WO2009026152A1 (en) | 2007-08-16 | 2008-08-15 | Metabolomic profiling of prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013227127A Division JP2014041154A (ja) | 2007-08-16 | 2013-10-31 | 前立腺癌の代謝プロファイリング法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010537170A JP2010537170A (ja) | 2010-12-02 |
| JP2010537170A5 true JP2010537170A5 (enExample) | 2011-09-29 |
| JP5406187B2 JP5406187B2 (ja) | 2014-02-05 |
Family
ID=40363136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521202A Active JP5406187B2 (ja) | 2007-08-16 | 2008-08-15 | 前立腺癌の代謝プロファイリング法 |
| JP2013227127A Pending JP2014041154A (ja) | 2007-08-16 | 2013-10-31 | 前立腺癌の代謝プロファイリング法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013227127A Pending JP2014041154A (ja) | 2007-08-16 | 2013-10-31 | 前立腺癌の代謝プロファイリング法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090047269A1 (enExample) |
| EP (2) | EP2179292B1 (enExample) |
| JP (2) | JP5406187B2 (enExample) |
| AU (1) | AU2008289172B2 (enExample) |
| CA (1) | CA2695674A1 (enExample) |
| WO (1) | WO2009026152A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2061899B1 (en) | 2006-09-19 | 2012-08-29 | Metabolon Inc. | Biomarkers for prostate cancer and methods using the same |
| WO2009020521A2 (en) | 2007-08-03 | 2009-02-12 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
| JP5754137B2 (ja) * | 2008-06-20 | 2015-07-29 | 味の素株式会社 | 前立腺癌の評価方法、前立腺癌評価装置、前立腺癌評価方法、前立腺癌評価プログラム、記録媒体、前立腺癌評価システム、および情報通信端末装置 |
| PL2438445T3 (pl) * | 2009-06-04 | 2014-12-31 | Metanomics Health Gmbh | Sposoby diagnozowania raków gruczołu krokowego |
| EP2488666A4 (en) * | 2009-10-13 | 2013-05-29 | Purdue Research Foundation | BIOMARKERS AND IDENTIFICATION METHOD FOR THE EARLY DETECTION AND PREDICTION OF THE REPRESENTATION OF BREAST CANCER BY NMR |
| EP3438656A3 (en) * | 2009-10-30 | 2019-05-01 | Keio University | Anticancer agent sensitivity-determining marker |
| JP2013515270A (ja) * | 2009-12-22 | 2013-05-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 前立腺癌の代謝学的プロファイリング |
| WO2011088030A1 (en) * | 2010-01-15 | 2011-07-21 | Bryan William Jones | Disease diagnosis and treatment using computational molecular phenotyping |
| EP2354794A1 (en) * | 2010-01-29 | 2011-08-10 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Diagnosing prostate cancer relapse |
| JP2011247869A (ja) * | 2010-04-27 | 2011-12-08 | Kobe Univ | メタボローム解析手法を用いた特定疾患の検査方法 |
| WO2011146683A1 (en) * | 2010-05-19 | 2011-11-24 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| CA2807811A1 (en) * | 2010-07-28 | 2012-02-02 | Metabolon Inc. | Biomarkers for prostate cancer and methods using the same |
| EP2841948A1 (en) * | 2012-04-27 | 2015-03-04 | Eastern Virginia Medical School | Quantitation of biomarkers for the detection of prostate cancer |
| WO2014074821A1 (en) * | 2012-11-09 | 2014-05-15 | Dana-Farber Cancer Institute, Inc. | Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer |
| WO2014089431A1 (en) * | 2012-12-06 | 2014-06-12 | Dana-Farber Cancer Institute, Inc. | Metabolomic profiling defines oncogenes driving prostate tumors |
| KR101462206B1 (ko) | 2013-06-26 | 2014-11-20 | 한국과학기술연구원 | 트립토판 대사 변화를 이용한 위암 진단용 기초 정보 제공 방법 |
| JP6222629B2 (ja) * | 2013-08-29 | 2017-11-01 | 花王株式会社 | 排尿障害のバイオマーカー |
| WO2015050366A1 (ko) * | 2013-10-04 | 2015-04-09 | 주식회사 씨스퀘어 | 사르코신 대사산물 중 포름알데히드 또는 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단 방법 |
| KR101838133B1 (ko) | 2013-10-04 | 2018-03-14 | 주식회사 씨스퀘어 | 사르코신 대사산물 중 포름알데히드를 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법 |
| GB201408875D0 (en) | 2014-05-19 | 2014-07-02 | Cambridge Oncometrix Ltd | Diagnostic method |
| WO2017210097A1 (en) | 2016-06-02 | 2017-12-07 | Metabolon, Inc. | Mass spectrometry method for detection and quantitation of metabolites |
| EP3490677A4 (en) * | 2016-07-07 | 2020-05-13 | Berg LLC | LIPID, PROTEIN AND METABOLIC MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER |
| KR101962882B1 (ko) | 2017-06-01 | 2019-03-28 | 한국과학기술연구원 | 구연산염 검출 센서 및 이를 이용한 구연산염 검출 방법 |
| CN114641690A (zh) * | 2019-09-03 | 2022-06-17 | 远景科学私人有限公司 | 用于确认、检测和评估前列腺癌进展的方法以及相关治疗 |
| WO2021138611A2 (en) * | 2020-01-03 | 2021-07-08 | Femtera Laboratories | Reliable metabolite biomarkers for multiple urological cancers |
| CN115552025A (zh) * | 2020-02-05 | 2022-12-30 | 克利夫兰诊所基金会 | 基于苯乙酰谷氨酰胺水平的疾病检测和治疗 |
| CN113804901B (zh) * | 2020-06-15 | 2023-06-23 | 南京市口腔医院 | 用于口腔鳞癌早期无创诊断的血清脂质标志物及其应用 |
| KR102379017B1 (ko) * | 2020-08-18 | 2022-03-28 | 서울대학교 산학협력단 | 13c 또는 2h 동위원소로 표지된 글라이신을 유효성분으로 포함하는 간암 진단용 조성물 |
| CN113440533B (zh) * | 2021-07-01 | 2022-02-01 | 江南大学 | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 |
| CN115184478A (zh) * | 2022-04-26 | 2022-10-14 | 沈阳药科大学 | 一种基于“纤维内衍生化”策略的血浆中70种氨基类物质的定量分析方法及其用途 |
| KR102719659B1 (ko) * | 2023-03-29 | 2024-10-17 | 경희대학교 산학협력단 | 퀴놀리늄계 화합물 및 이의 제조방법, 시트르산염 검출센서, 전립선암 진단센서 및 전립선암 진단방법 |
| TW202528739A (zh) * | 2023-09-05 | 2025-07-16 | 國立臺灣大學 | 用於前列腺癌的生物標記 |
| GB2634269A (en) * | 2023-10-04 | 2025-04-09 | Aberystwyth Univ | Biomarkers for prostate cancer |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| FI875739A0 (fi) * | 1986-04-28 | 1987-12-28 | Boehringer Mannheim Gmbh | Foerfarande och reagens foer paovisning av hjaertskador eller -sjukdomar. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
| US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| KR100334858B1 (ko) | 1993-02-19 | 2006-01-27 | 니뽄 신야쿠 가부시키가이샤 | 핵산공중합체를함유하는의약조성물 |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| CA2203809C (en) | 1994-10-28 | 2008-06-03 | James M. Wilson | Recombinant adenovirus and methods of use thereof |
| US5872154A (en) | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| US6020139A (en) * | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
| US6019978A (en) | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US5854206A (en) | 1995-08-25 | 1998-12-29 | Corixa Corporation | Compounds and methods for treatment and diagnosis of prostate cancer |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| EP0914335A2 (en) | 1996-03-15 | 1999-05-12 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
| EP1005546A2 (en) | 1997-02-25 | 2000-06-07 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| US6080912A (en) | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
| ES2324503T3 (es) | 1997-04-10 | 2009-08-07 | Stichting Katholieke Universiteit University Medical Centre Nijmegen | Pca3, genes pca3 y metodos de uso. |
| US5830730A (en) | 1997-05-08 | 1998-11-03 | The Regents Of The University Of California | Enhanced adenovirus-assisted transfection composition and method |
| AU756549B2 (en) | 1997-07-11 | 2003-01-16 | Crucell Holland B.V. | Interleukin-3 gene therapy for cancer |
| US5972639A (en) | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
| US6300136B1 (en) * | 1997-09-03 | 2001-10-09 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis and treatment of tumors in humans |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| JP2003528029A (ja) | 1998-08-14 | 2003-09-24 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 遺伝子治療用のアデノウイルス配合物 |
| WO2000012738A1 (en) | 1998-08-27 | 2000-03-09 | Aventis Pharma S.A. | Targeted adenovirus vectors for delivery of heterologous genes |
| US6828429B1 (en) | 1999-03-26 | 2004-12-07 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer |
| WO2001078652A2 (en) * | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| US7329489B2 (en) * | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| WO2001098754A1 (en) | 2000-06-22 | 2001-12-27 | Atto Instruments Llc | High efficiency cell analysis system and high throughput drug screening system |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US20030134677A1 (en) * | 2001-09-27 | 2003-07-17 | Salah Obied | Method and apparatus for generating real-time embedded software for a chance game |
| US20070078093A1 (en) * | 2003-10-16 | 2007-04-05 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating cancer |
| JP2005162714A (ja) * | 2003-12-05 | 2005-06-23 | Shoken Seika Kagi Kofun Yugenkoshi | グリシンｎメチルトランスフェラーゼモノクローナル抗体およびその使用方法 |
| US20060010505A1 (en) | 2004-06-18 | 2006-01-12 | Washington University | High throughput cancer pharmaceutical screening using drosophila |
| US20070055456A1 (en) | 2005-08-31 | 2007-03-08 | Daniel Raftery | NMR method for differentiating complex mixtures |
| EP2061899B1 (en) * | 2006-09-19 | 2012-08-29 | Metabolon Inc. | Biomarkers for prostate cancer and methods using the same |
-
2008
- 2008-08-15 US US12/192,681 patent/US20090047269A1/en not_active Abandoned
- 2008-08-15 CA CA2695674A patent/CA2695674A1/en not_active Abandoned
- 2008-08-15 EP EP08827819A patent/EP2179292B1/en active Active
- 2008-08-15 JP JP2010521202A patent/JP5406187B2/ja active Active
- 2008-08-15 AU AU2008289172A patent/AU2008289172B2/en active Active
- 2008-08-15 EP EP12194382.3A patent/EP2597464B1/en not_active Not-in-force
- 2008-08-15 WO PCT/US2008/073318 patent/WO2009026152A1/en not_active Ceased
-
2013
- 2013-10-31 JP JP2013227127A patent/JP2014041154A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010537170A5 (enExample) | ||
| Radaic et al. | Biological biomarkers of oral cancer | |
| Tang et al. | Strand displacement-triggered G-quadruplex/rolling circle amplification strategy for the ultra-sensitive electrochemical sensing of exosomal microRNAs | |
| Han et al. | Development and validation of a rapid, selective, and sensitive LC–MS/MS method for simultaneous determination of d-and l-amino acids in human serum: application to the study of hepatocellular carcinoma | |
| US20220026433A1 (en) | Cleavable fluorescent tyramide for sensitive and multiplexed analysis of biological samples | |
| Cheng et al. | A translational study of urine miRNAs in acute myocardial infarction | |
| Maeda et al. | Significance of postmortem biochemistry in determining the cause of death | |
| WO2018171947A1 (en) | Tissue-derived extracellular vesicles and their use as diagnostics | |
| WO2014150900A1 (en) | Methods and compositions for enhanced analyte detection from blood | |
| EP2402463A3 (en) | Nucleic acid molecules and collections thereof, their application and identification | |
| ES2656896T3 (es) | Metilglioxal como marcador de cáncer | |
| Li et al. | The impact of L-type amino acid transporter 1 (LAT1) in human hepatocellular carcinoma | |
| US20140030727A1 (en) | Loss of 5-hydroxymethylcytosine as a biomarker for cancer | |
| Liu et al. | An amplification strategy using DNA-Peptide dendrimer probe and mass spectrometry for sensitive MicroRNA detection in breast cancer | |
| WO2021155858A1 (zh) | 一种基于DSN循环扩增技术同时检测多种microRNA的液相色谱法 | |
| US20250312019A1 (en) | Kits for stabilization of urine samples at room temperature | |
| Decmann et al. | Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy | |
| Chrzanowska et al. | Significance of arginase determination in body fluids of patients with hepatocellular carcinoma and liver cirrhosis before and after surgical treatment | |
| Yu et al. | Nanoconfinement effect based in-fiber extraction and derivatization method for ultrafast analysis of twenty amines in human urine by GC-MS: Application to cancer diagnosis biomarkers’ screening | |
| Deng et al. | Urinary biomarkers for hepatocellular carcinoma: current knowledge for clinicians | |
| CN102633694B (zh) | 一种检测巯基化合物的荧光探针及其制备方法与使用方法 | |
| Wu et al. | Establishment of a direct quantitative method for measurement of microRNA-224 in serum by UHPLC/MS/MS | |
| Kågedal et al. | Failure of the PAXgene™ Blood RNA System to maintain mRNA stability in whole blood | |
| ES2528672B1 (es) | Neurofilina-1 (NRP-1) urinaria como marcador pronóstico de nefritis y nefritis lúpica | |
| Hayashi et al. | Use of serum and urine metabolome analysis for the detection of metabolic changes in patients with stage 1-2 chronic kidney disease |